YK-11
Steroidal SARM inducing follistatin; myostatin pathway modulator
Mechanism of Action
YK-11 is a synthetic steroidal compound (derivatized from DHT backbone) classified as a SARM, though its primary mechanism is distinct from conventional non-steroidal SARMs. YK-11 acts as a partial AR agonist but uniquely induces expression of follistatin (FST), a myostatin (GDF-8) antagonist. Myostatin is a negative regulator of muscle mass; by increasing follistatin, YK-11 may promote skeletal muscle hypertrophy via dual AR-mediated and myostatin-inhibition pathways. This mechanism is supported by in vitro data showing increased myogenic differentiation in C2C12 myoblasts. No human clinical trials have been conducted as of current data.
Evidence Chain
YK-11
COMPOUND
1 Research Goal
• Muscle & Tissue Growth
Evidence Strength
5 articles sourced
Knowledge Graph
(6 connections)Research Evidence
(5)Enobosarm (Ostarine / MK-2866): Evidence-Based Research Review
**Class:** SARM (Selective Androgen Receptor Modulator)
YK-11 vs RAD-140: Evidence-Based Comparison
Selective Androgen Receptor Modulators (SARMs) are a class of therapeutic compounds with similar anabolic properties to anabolic steroids but with reduced androgenic activity. This article compares YK-11 and RAD-140 (Testolone), two of the most potent compounds currently discussed in sports pharmaco
YK-11: Evidence-Based Research Review
YK-11 (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester is a synthetic compound classified as a Selective Androgen Receptor Modulator (SARM). Unlike traditional non-steroidal SARMs such as Ostarine or Ligandrol, YK-11 possesses a steroidal
Testolone (RAD-140): Evidence-Based Research Review
Testolone (RAD-140) is a potent, non-steroidal selective androgen receptor modulator (SARM) originally developed by Radius Health, Inc. It was designed to overcome the limitations of conventional androgen therapy, such as prostate enlargement and virilization, by exhibiting high tissue selectivity.
Andarine (S-4): Evidence-Based Research Review
Andarine (also known as S-4 or GTx-007) is an early-generation, nonsteroidal selective androgen receptor modulator (SARM) belonging to the aryl propionamide class. Developed initially for the treatment of conditions such as muscle wasting and osteoporosis, Andarine demonstrates high affinity for the
Related Compounds
Synergy & Compatibility
(5)Computational assessment of bio-regulatory compatibility with compounds sharing research goals. Scores reflect half-life alignment, receptor target overlap, and bioavailability data.
Highest Compatibility
YK-11 + Nandrolone Decanoate
High Compatibility
Computational assessment based on available pharmacology data. Does not account for individual variability, dose-dependent effects, or unstudied interactions. For research use only.
Community Observations
(0)Qualitative, self-reported researcher observations. Distinct from peer-reviewed evidence — not medical advice.
No approved observations yet. Sign in to contribute.
For research use only. Not medical advice.